- Hi, I'm Frederik Zimmermann. I'm from the Catharina Hospital in Eindhoven in the Netherlands and I will talk about the quality of life analysis, the FAME 3 Trial.
Study Rationale
So, previous studies have shown that revascularisation improves quality of life and more so after CABG than PCI. However, previous trials did not use FFR to guide PCI and did not use second-generation drug-eluting stents, both of which have been shown to improve outcome. For that reason, the FAME 3 study was conducted, which was an investigator-initiated, multicentre, international, randomised controlled trial in 48 sites worldwide, comparing FFR-guided PCI with CABG in patients with three-vessel disease. As presented by Dr Fearon last year at TCT, and also published in New England Journal of Medicine, PCI did not meet noninferiority with respect to MACE at one year. However, if you look at the event rates compared to previous trials, then the event rates are lower and the differences between PCI and CABG narrow. So in light of the smaller differences in event rates, the quality of life angina status, as well as working status, becomes much more important for clinical decision making.
Study Design and Patient Cohort
So, for this quality of life analysis, our primary endpoint was the EQ-5D summary index at one year. We assessed quality of life at baseline, one month and 12 months, as well as the Visual Analogue Scale of the EQ-5D. Angina status and working status were also assessed at that point but also at six months.
Key Findings
We found that quality of life at one year was identical between the FFR-guided PCI group and the CABG group. However, FFR-guided PCI resulted in faster improvement of quality of life. We also found that the angina was dramatically decreased over both forms of revascularisation, with no differences at 12 months and working. And patients in the CABG arm worked less at one month. Interestingly, if we looked at a pre-specified subgroup analysis of patients younger than 65 years old at time of randomisation, we found that patients in the CABG group worked less at one month but also at six months and 12 months.
Take-home Messages for Clinicians
In light of the low event rates, it's all about shared decision-making with the patients. And we now have the data. We're very confident that the quality of life improves faster after FFR-guided PCI, with no differences also with respect to angina at one year.
Further Study Required
It will also be important to look at longer follow-up. So, we will also follow patients for up to five years. We will do the quality of life analysis at three and five years. I have to say, though, that in previous studies such as SYNTAX and FREEDOM, the main findings did not change that much beyond one year, with respect to quality of life.
ACC 2022: Late-breaking Science Video Collection
Published: 05 April 2022
-
Views:
7614
-
Likes:
7
-
Views:
7614
-
Likes:
7
-
Up Next -
3m 54sPart 3 | Session 5 ACC 22: Results from the TRANSLATE-TIMI 70 Trial
-
4m 22sPart 3 | Session 6 ACC 22: Results from the POISE-3 Trial
-
6m 30sPart 3 | Session 7 ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia
-
6m 3s
-
3m 31sPart 3 | Session 9 ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)
-
4m 48sPart 3 | Session 10 ACC 22: Results From a sub-study of the POISE-3 Trial
-
2m 55sPart 3 | Session 11 ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials
-
7m 44sPart 3 | Session 12 ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR
-
5m 41sPart 3 | Session 13 ACC 22: Results From the Chocolate-Touch Study
-
2m 25sPart 3 | Session 14 ACC 22: Results from the GIPS-IV Trial
-
9m 27s
-
5m 35s
-
10m 24s
-
3m 50sPart 3 | Session 18 ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study
-
4mPart 3 | Session 19 2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation
-
12m 6sPart 4 | Session 1 ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani
-
6m 15s
-
7m 9sPart 4 | Session 3 4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos
-
23m 9sPart 1 | Session 1 ACC 22 Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
28m 6sPart 1 | Session 2 ACC.22 Late-breaking Science Wrap-Up Nicolas M Van Mieghem, Joost Daemen
-
16m 42sPart 2 | Session 1 ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial Justin Ezekowitz, Harriette Van Spall
-
16m 57sPart 2 | Session 2 ACC 2022 Late-breaker Discussion: The SuperWIN Trial Harriette Van Spall, Dylan L Steen
-
15m 38sPart 2 | Session 3 ACC 22 Late-breaker Discussion: The PROMPT-HF Trial Harriette Van Spall, Gregg C Fonarow, Tariq Ahmad
-
22m 47sPart 2 | Session 4 ACC 22 Late-breaker Discussion: The DIAMOND Trial Harriette Van Spall, Javed Butler, Faiez Zannad
-
9m 38sPart 3 | Session 1 ACC 22: Findings from the VALOR-HCM Trial Milind Y Desai
-
7m 19sPart 3 | Session 2 ACC 22: MAVA-LTE Shows Improvement in NYHA Class in Patients Treated with Mavacamten Florian Rader
-
3m 19sPart 3 | Session 3 ACC 22: Results From the PACIFIC AF Trial Manesh R Patel
Overview
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
View from the Thoraxcenter
In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022.
Part 2
Late-breaker Discussion Series
Host, Dr Harriette Van Spall interviews the late-breaker presenters of ACC Scientific Sessions 2022.
Part 3
Expert Interviews
Faculty Biographies
Frederik Zimmermann
Dr Frederik Zimmermann is an interventional cardiologist at Catharina Hospital, Eindhoven, NL.
Transcript